Cargando…
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also castration-resistant prostate cancer (CRPC) is dependent on functional AR, and several mechanisms have been proposed to explain the addiction. Known causes of CRPC include gene amplification and overexpressi...
Autores principales: | Moilanen, Anu-Maarit, Riikonen, Reetta, Oksala, Riikka, Ravanti, Laura, Aho, Eija, Wohlfahrt, Gerd, Nykänen, Pirjo S., Törmäkangas, Olli P., Palvimo, Jorma J., Kallio, Pekka J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394/ https://www.ncbi.nlm.nih.gov/pubmed/26137992 http://dx.doi.org/10.1038/srep12007 |
Ejemplares similares
-
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015) -
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021) -
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017) -
SUN-LB002 CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
por: Oksala, Riikka, et al.
Publicado: (2019) -
OR07-6 Disrupting DNA-binding Domain Dimerization In The Androgen Receptor In Mice Results In a Partial Androgen Insensitivity Model
por: Claessens, Frank, et al.
Publicado: (2022)